Johnson Investment Counsel Inc Ligand Pharmaceuticals Inc Transaction History

Johnson Investment Counsel Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$150.77 - $207.98 $319,330 - $440,501	-2,118 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$138.63 - $182.62 $3,188 - $4,200	-23 Reduced 1.07%	2,118 $349,000
Q4 2017 Feb 14, 2018	BUY	$128.36 - $147.04 $5,647 - $6,469	44 Added 2.1%	2,141 $293,000
Q3 2017 Nov 14, 2017	BUY	$120.91 - $137.94 $253,548 - $289,260	2,097	2,097 $285,000

277

18.5M

30.8K

5.2K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.83B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Johnson Investment Counsel Inc, based on Form 13F filings with the SEC.

Stay updated on Johnson Investment Counsel Inc with notifications on news.